introduction
Adult soft-tissue sarcoma (STS) represents a heterogeneous group of rare malignancies, accounting for around 1%-2% of all adult cancers [1] . Overall survival after STS is around 50%-60% at 5 years, [2] with a 10%-20% risk of local recurrence, and approximately 30%-40% of patients develop metastatic disease. This low incidence and considerable heterogeneity of pathological diagnoses, locations, and prognostic factors, make the clinical management of these highly malignant tumors difficult, especially when the lump is first discovered in primary care. Poor or moderate adherence with clinical practice guidelines (CPGs) from diagnosis to care practices is frequently reported [3] [4] [5] [6] .
Histological difficulties and multiple coding systems (tumor morphology or anatomic site) have also resulted in variability in the estimation of incidence rates [7] . The estimated standardized incidence rate for STS is generally reported around 1.7 [8] -2.4 [9, 10] , but can be up to 3.6 [11] per 100 000 inhabitants. These differences can be explained by the reference population selected for standardization, study setting, or selection of histological types.
Given the documented variation in STS care and the lack of clear incidence data and within the framework of the CONnective Tissues Cancers NETwork project [12] , this prospective population-based study used active recruitment and multiple information sources to examine practices in STS care management in terms of adherence with expert-determined guidelines, and to investigate factors associated with lower adherence. A secondary aim was to provide standardized incidence rates.
patients and methods
All adult patients (≥18 years old) diagnosed between 1 November 2006 and 31 December 2007 in the Aquitaine and Midi-Pyrénées administrative districts in South-West France (6 million inhabitants, 10% of the French population) with primary STS of any stage were included. Patients with visceral, bone, uterus or Kaposi's sarcoma, gastrointestinal stromal tumors, or mesotheliomas were not included since their presentation, diagnosis, management, and overall prognosis are quite different than those with STS. Patients being treated for recurrence, and patients diagnosed outside of the administrative districts were not eligible. STS diagnoses were made in public or private pathology laboratories. Data were collected from all relevant sources: pathology reports, medical records from private and public centers, data from the district cancer registries, and weekly multidisciplinary team (MDT) meeting reports from regional cancer networks. French National Commission on Information Technologies and Liberties approved this study.
data collection
Patient management was recorded in terms of: diagnosis, pretherapeutic work-up, assessment of disease extension, surgery, pathology, quality of surgery according to the Union for International Cancer Control (UICC)-R classification, discussion in MDT meetings, and radiotherapy or adjuvant chemotherapy. Tumor depth was defined as 'superficial' if it was a supra-aponeurotic tumor of the skin and/or the hypoderm (complete information on data collection is available in supplementary material, available at Annals of Oncology online).
development of quality-of-care criteria: Delphi consensus method
We used the DELPHI consensus method [13, 14] to develop criteria for the quality of care through consultation with selected French national sarcoma group experts (Groupe Sarcome Français-GSF). We selected key elements from available CPG and relevant literature, and drafted a written questionnaire. A multidisciplinary panel of 19 national experts discussed and rated the potential quality-of-care criteria and selected a final set that we report according to the level of consensus ( perfect, high, or good) (details in supplementary material, available at Annals of Oncology online).
statistical considerations
Adherence rates were calculated for each criterion as the number of patients receiving the treatment or care as set out by the criterion ('patients observed') divided by the number of patients to whom the criterion applied (for example, surgery quality criteria only applied to patients receiving surgery).
Three composite criteria were constructed to describe practices. The first two criteria relate to diagnosis practices: (i) imaging: compliant for patients with deep tumors if they received magnetic resonance imaging (MRI) or scan of the tumor zone before surgery (Delphi 1), and for patients with superficial tumors if they received an MRI, scan, or ultrasound before surgery (for all operated patients) (Delphi 6); (ii) diagnostic method (biopsy): compliant for deep tumors over 5 cm in size or tumors <5 cm increasing in size, if the diagnosis was made from a percutaneous or surgical biopsy. All methods for superficial or deep tumors <5 cm not increasing in size were considered as a compliant unless there was no information on depth or it was a deep tumor with no information on size or possible increase in size (Delphi 2 and 3). (iii) MDT discussion: compliant if patient file discussed in MDT meetings ( Delphi 8, 11, 15, 17, 18, and 23) , with the added condition that MDT discussion must have occurred before or within 31 days of diagnosis for all tumor types.
Based on the literature, we selected the following factors to test for associations with adherence on these three composite criteria: age at diagnosis [6] , tumor site (limbs, head, and neck or trunk wall versus internal trunk) [7] , histological grade (1 versus 2/3 versus nongradable) [6] , and the type of institution offering the care (specialized versus nonspecialized treatment centers) [5, 6] . Logistic regression was used to model the probability of adherence. We calculated age and sex-standardized incidence rates based on standard populations: French [15] , European [16, 17] , World [18] , US theoretical population of 1 million, and the year 2000 projected US population [19] . SAS 9.2 was used for all analyses. Additional details on the statistical analysis are provided in supplementary material, available at Annals of Oncology online.
results
Overall, 274 adult STS diagnoses were recorded in this study. Patients' characteristics are given in Table 1 .
practices observed and adherence with guidelines
Over 70% of patients received guideline-compliant care for four of the eight diagnostic criteria (Table 2) : MRI/scan before surgery for deep tumors (Delphi 1: 81.5%), tumor characteristics determined (Delphi 4: 92.7%), thoracic scan received (Delphi 5: 70.8%), and secondary histological review (Delphi 7: 75.2%). Moderate adherence was observed for two criteria: histological diagnosis before surgery for patients with deep, rapidly increasing, or >5 cm in size tumors (Delphi 2: 51.7%), and adequate biopsy technique (Delphi 3: 55.5%). The lowest adherence was observed for two criteria: only 37.1% of patients with superficial tumors received imaging before surgery (Delphi 6), and only 6.4% of patients' files were discussed at MDT meetings before biopsy (Delphi 8).
In other words, irrespective of the relevant population considered for adherence for each criterion, we observed that almost three quarters of patients received imaging of the tumor region before surgery (72.6%) (supplementary Table S1 , available at Annals of Oncology online). Less than half of patients overall received thoracic imaging or abdominal imaging before surgery (44.9% and 43.8%, respectively), but at least 88.9% of those with retroperitoneum, pelvis, and intra-thoracic or -abdominal sites received thoracic or abdominal imaging (data not shown). More than four of 10 patients did not receive a biopsy and histological diagnosis before surgery. Most patients' records were discussed in MDT meetings at some stage during their care (80.7%). Pathology reports were generally compliant with guidelines (Table 2 ) (Delphi 9: 73.8%), with the least compliant aspect of this criteria being the reporting of surgical margins.
Overall, 85.3% of patients (n = 234) received surgery; 40.9% radiotherapy (n = 112) and 27% chemotherapy (n = 74) (supplementary Table S1 , available at Annals of Oncology online). Initial surgery was carried out in a specialized treatment center for 93 (39.7%) of patients. Of the remaining 141 patients who received initial surgery outside of specialized centers, 67 (47.5%) were subsequently referred to a specialized center for continuing care (MDT discussion or treatment), and 74 (52.5%) received further care in a nonspecialized hospital. Overall, 92 patients had an initial R1 resection; among the 43 (47%) patients who required a second operation, 38 (88%) had the first surgery outside of specialized centers, and 5 (12%) in a specialized center. Only 29.9% of eligible patients' cases were discussed in an MDT meeting before surgery (Table 2) (Delphi 11), although adherence was better for unresectable tumors (63.8% discussion in MDT meetings, Delphi 12) and metastatic patients (74.3% discussion in MDT meetings, Delphi 14) . Reporting the assessment of surgical margins (positivity or negativity) was largely compliant (78.6%, Delphi 13). 
adherence for major criteria
Of the 261 eligible patients overall (13 did not receive treatment), diagnostic imaging practices (criterion 1) were compliant for 64.4% of patients; biopsy methods (criterion 2) for 67.0%, and MDT discussion within 31 days (criterion 3) for 47.1%.
After adjustment for age and sex, factors associated with less adherence for diagnostic imaging practices (criterion 1) were: tumor site (limbs, head, and neck, or trunk wall) [odds ratio (OR) 3.03, 95% confidence interval (CI) 1.18-7.78], superficial tumors (OR 3.70, 95% CI 1.80-7.61), and treatment in a nonspecialized center (OR 5.69, 95% CI 2.74-11.85) ( Table 3) . Factors associated with less adherence for biopsy methods (criterion 2) were: tumor site (internal trunk) (OR 4.17, 95% CI 2.21-7.86) and treatment in a nonspecialized center (OR 3.20, 95% CI 1.45-7.05). For MDT discussion within the recommended timeframe (criterion 3), factors associated with lower adherence were: superficial tumors (OR 1.77, 95% CI 1.12-2.80) and treatment in a nonspecialized center (OR 3.23, 95% CI 1.73-6.06).
Soft-tissue sarcoma incidence
Of the 274 new cases of adult STS diagnosed in this study, 211 were eligible for the estimation of incidence over the 2007 calendar year (diagnosis made in 2006 for other patients, or they were resident outside of the two defined areas). The standardized incidence rate per 100 000 inhabitants was 3.33 based on the IARC and WPP populations (supplementary Table S2 , available at Annals of Oncology online).
discussion
This prospective population-based observational study evaluates STS patient care and management across two French regions and provides robust estimation of standardized STS incidence. We used active recruitment from multiple sources to ensure completeness of recruitment, and in particular, we focused on identifying and explaining areas of low adherence with recommended practices. For this, we developed a set of 23 criteria covering initial care management in primary STS.
Patient characteristics were relatively similar to previous reports [7, 20] . Globally, although practices were relatively compliant (70% and over for 10 criteria), we identified major areas for improvement (under 50% adherence for five criteria). Of the nine undisputable criteria for standards of care ( perfect consensus and reported in all recent STS clinical guidelines, e.g. [21] ), adherence was particularly low for three: receiving initial histological diagnosis before surgery, adequacy of the biopsy technique (around 50% for both), and discussion in an MDT meeting before surgery (<30%). These areas represent a crucial need for improvement in practices, particularly given that over 4 in 10 patients receive surgery before receiving a histological diagnosis. This figure may be partially represented by a number of inadvertent initial operations, or 'whoops surgeries'. These unplanned excisions of unsuspected STS lesions originally considered to be benign were estimated to represent up to 40% of all initial operations for STS [22] and have been reported to have negative impacts on patient survival [23] , as recently reported for the lack of adherence to locoregional treatment and chemotherapy guidelines [20] .
Adherence with general surgical standards was concerning with over one in four patients not receiving any imaging before surgery, showing no improvement since a previous report [24] . Further, over 50% did not receive initial surgery in a specialized treatment center, although receiving treatment at high-volume specialized centers has been clearly identified as improving local control [25] and survival, irrespective of grade [26] [27] [28] . This represents an important area for educational interventions aimed at increasing sarcoma awareness and knowledge for surgeons and raising patients' awareness of the importance of seeking specialized care. This low adherence for imaging and nonspecialized center procedures emphasizes the need for a correct sarcoma diagnosis from the outset, so that patients can be directed early to centers with significant experience dealing with these rare malignancies, especially when coupled with issues involving the lack of, or delay for discussion in MDT meetings.
Our data indicate that MDT meetings are happening, with more than three quarters of patients' records discussed at some stage in an MDT meeting, similar to rates reported in the literature [29] .
Finally, the multivariate analysis reveals that patients particularly at risk of low adherence are those receiving treatment outside of a specialized center, those with superficial tumors, and those with tumors of the internal trunk for biopsy methods and those with limbs, head, neck, and trunk wall tumors for diagnostic imaging.
Our incidence results provide a good estimation of adult STS with multisource active recruitment. Using a comparable population of adults over 20 years, the adult-only incidence rate is similar to the rate reported in another French region [7] . Indeed, as recently reported [30] , a collaborative method including complete cancer registry and pathology laboratory data is recommended to obtain better incidence estimation for sarcoma.
Some limitations of this observational study should be mentioned. These regions have extremely active networks for sarcoma and rare tumors, which may result in an overestimation of adherence for certain results if extended nationally across other regions with less active networks. An observation bias can also not be ruled out. When interpreting the lack of MDT meetings for patients initially treated in nonspecialized centers, it should be kept in mind that MDT meetings are not physically held at the nonspecialized centers, who refer patients to specialized centers for MDT sarcoma discussion. This association may therefore represent a delay before MDT discussion rather than a lack of discussion. In addition, these practices date from 2007, just after the implementation of sarcoma guidelines. Changes have since taken place in practices with secondary histological review being recommended at the time of study, but mandatory since 2010 at the national level (www.rreps.org), and MDT reports now systematically registered (www.netsarc.org).
conclusion
This report on practices in STS care, using multiple source data, offers a robust description of practices requiring improvement. Future interventions should focus on biopsy methods for internal trunk and superficial tumors, diagnostic imaging for limbs, head, neck, and trunk wall superficial tumors, or timely MDT discussion, in particular for patients treated outside of specialized centers. However, if, and when, diagnosis is correct, patient care appears relatively compliant with CPGs.
